- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01009099
Reducing Dynamic Hyperinflation Through Breathing Retraining
February 2, 2015 updated by: US Department of Veterans Affairs
This study will compare the effects of exercise training and breathing retraining (using metronome tones) to exercise training only.
Exercise training lasts 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Dynamic hyperinflation limits exercise tolerance in chronic obstructive pulmonary disease (COPD).
To limit dynamic hyperinflation during exercise and thus improve exercise tolerance, we successfully developed a visual-auditory ventilation-feedback system.
The system retrains patient's breathing pattern during exercise.
The goal of the current proposal was to develop a user-friendly ventilation-feedback technique with a novel auditory feedback system.
We reasoned that the proposed feedback system plus exercise training would be superior to exercise training alone while having the potential for an easier application into clinical practice.
Hypotheses: The primary hypothesis is that the exercise duration of patients with moderate-to-severe COPD who successfully complete a 12-week program of breathing retraining plus exercise will be longer than that of patients who complete a 12-week program of treadmill exercise training alone.
We also hypothesized that the primary predictor of improved exercise duration will be a reduction in dynamic hyperinflation and to a lesser extent, improvement in peripheral muscle function.
Lastly, we hypothesize that dyspnea will be reduced in patients assigned to breathing retraining plus exercise when compared to exercise training alone.
Methods: The proposed study was a randomized controlled clinical trial.
119 patients with moderate-to-severe COPD were randomized into breathing retraining plus exercise or exercise training alone.
Both groups received 12-weeks of treadmill exercise training three times weekly.
The breathing retraining plus exercise group also received auditory feedback to decrease respiratory rate and prolong exhalation.
The goal of breathing retraining was to reduce exercise-induced dynamic hyperinflation.
Follow-up testing was completed at 6, 12, and 24 weeks.
Testing included a pulmonary function test, symptom-limited and constant workrate treadmill tests, six-minute walk, dyspnea measurements, testing of respiratory muscle strength and endurance, and quadriceps muscle endurance testing.
Analysis: Measures of central tendency will be used to describe the study sample.
A two-sample t-test ( = 0.05) was used to analyze changes from baseline to 12-weeks between the breathing retraining plus exercise group and exercise training alone group.
In data analysis, intention-to-treat principles were used.
Since several measures will be taken on each patient, mixed-models analysis will be used to compare changes over time between the two groups.
Multiple regression analysis will be employed to determine the predictors of improved exercise performance.
Study Type
Interventional
Enrollment (Actual)
119
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Hines, Illinois, United States, 60141-5000
- Edward Hines, Jr. VA Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 40 yr of age
- FEV1 70%
- FEV1/FVC < 70%
- RV/TLC 120%
- mean SpO2 90% at peak exercise (w/ or w/o O2)
- Able to hear metronome sounds Lives near Hines, IL (Chicagoland area)
Exclusion Criteria:
- Respiratory infection/exacerbation within the previous four weeks
- Exercise limiting heart disease (+ stress test or other indicators of heart disease or complaints of angina during the stress test)
- Primary asthma
- Congestive heart failure (New York Heart Association Class III or IV)
- Exercise-limiting peripheral arterial disease (stops exercise due to intermittent claudication)
- Stops exercise due to arthritic pain in the knee or hips (self-report)
- Inability to walk on the treadmill
- Pregnancy
- Any unforeseen illness or disability that would preclude exercise testing or training
- Participation in a formal exercise program within the previous 12 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Arm 1
exercise training with breathing retraining
|
breathing retraining using a metronome
treadmill exercise training
|
|
ACTIVE_COMPARATOR: Arm 2
exercise training
|
treadmill exercise training
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise Duration (Time Walked on the Constant Workrate Treadmill Test)
Time Frame: baseline and 12 weeks
|
The primary outcome measure is a comparison of time walked on the constant workrate treadmill best at 12 weeks.
|
baseline and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (ACTUAL)
January 1, 2014
Study Completion (ACTUAL)
January 1, 2015
Study Registration Dates
First Submitted
November 5, 2009
First Submitted That Met QC Criteria
November 5, 2009
First Posted (ESTIMATE)
November 6, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
February 18, 2015
Last Update Submitted That Met QC Criteria
February 2, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F6955-R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease, COPDNew Zealand
-
AstraZenecaParexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease COPDUnited States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary Disease (COPD)Kyrgyzstan
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease, COPDGermany
-
AstraZenecaQuintiles, Inc.Completed
Clinical Trials on breathing retraining
-
Naestved HospitalActive, not recruiting
-
University of NebraskaNational Institute of Nursing Research (NINR)WithdrawnChronic Heart FailureUnited States
-
Riphah International UniversityRecruitingBlood Pressure | Orthostatic Hypotension | Heart RatePakistan
-
Royal Brompton & Harefield NHS Foundation TrustUniversity College London Hospitals; Guy's and St Thomas' NHS Foundation TrustRecruitingAnxiety | Post-COVID-19 Syndrome | BreathlessnessUnited Kingdom
-
University of NebraskaNational Institute of Nursing Research (NINR)Terminated
-
US Department of Veterans AffairsCompleted
-
VA Office of Research and DevelopmentCompleted
-
Palo Alto Veterans Institute for ResearchVA Palo Alto Health Care SystemCompletedDriving Distress Secondary to Trauma During DeploymentUnited States
-
Cairo UniversityNational Heart Institute, EgyptCompletedChronic Heart FailureEgypt
-
University College DublinMater Misericordiae University Hospital; Irish Cancer SocietyRecruitingPsychological Distress | Cancer RecurrenceIreland